The Sanofi logo is seen on the facade of the company’s headquarters in Gentilly, near Paris, France on December 11, 2020.
Chesnot | Getty Images
Singapore-French pharmaceutical manufacturer Sanofi On Wednesday, the company opened an S$800 million ($595 million) “Evolved Vaccine Facility” (EVF) in Singapore, the only such facility it owns outside France.
The plant, known as Modulus, can switch to producing different vaccines or treatments in a matter of days, whereas more traditional facilities would take weeks or months. It is also capable of producing up to four vaccines or biopharmaceuticals simultaneously.
The facility will provide around 200 jobs to the city-state, including bioprocess engineers, automation experts and data analysts, and will be fully operational by mid-2026.
Sanofi said in a news release that the facility has the potential to significantly enhance pandemic preparedness efforts.
“By laying the foundation for critical production modules now, Modulus can ensure a rapid, targeted response to any future health needs, including potential pandemics,” the company said.
This is part of the company’s 900 million euro investment to develop two new EVFs globally within five years. Another EVF is located in Neuville-sur-Saône, France.
